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Abstract
Background—Lymph node metastases are prognostically significant in pancreatic ductal
adenocarcinoma. Little is known about the significance of direct lymph node invasion.
Aim—The aim of this study is to find out whether direct lymph node invasion has the same
prognostic significance as regional nodal metastases.
Methods—Retrospective review of patients resected between 1/1/1993 and 7/31/2008. “Direct”
was defined as tumor extension into adjacent nodes, and “regional” was defined as metastases to
peripancreatic nodes.
Results—Overall, 517 patients underwent pancreatic resection for adenocarcinoma, of whom 89
had one positive node (direct 26, regional 63), and 79 had two positive nodes (direct 6, regional
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68, both 5). Overall, survival of node-negative patients was improved compared to patients with
positive nodes (N0 30.8 months vs. N1 16.4 months; p<0.001). There was no survival difference
for patients with direct vs. regional lymph node invasion (p=0.67). Patients with one positive node
had a better overall survival compared to patients with ≥2 positive nodes (22.3 and 15 months,
respectively; p<0.001). The lymph node ratio (+LN/total LN) was prognostically significant after
Cox regression (p<0.001).
Conclusions—Isolated direct invasion occurs in 20% of patients with one to two positive nodes.
Node involvement by metastasis or by direct invasion are equally significant predictors of reduced
survival. Both the number of positive nodes and the lymph node ratio are significant prognostic
factors.
Keywords
Pancreatic ductal adenocarcinoma; Direct lymph node invasion; Lymph node ratio
Introduction
Pancreatic cancer is the fourth leading cause of cancer death in the USA. The American
Cancer Society estimates that 42,470 people will be diagnosed with pancreatic cancer and
35,240 will die of the disease in 2009.1 Approximately 10–20% of patients diagnosed with
pancreatic ductal adenocarcinoma harbor resectable tumors. However, overall survival
continues to be poor even for resected patients, with a median survival of 17 to 18 months
and a 5-year survival of 12–18%.2–6
Many studies have documented the prognostic significance of positive lymph nodes.
Patients with lymph node metastases have a significantly lower 5-year survival rate than
patients with node negative disease.3–5,7 The number of positive lymph nodes also appears
to influence patient survival with two or more positive nodes associated with a worse
outcome.6,8 Prospective randomized trials have evaluated the role of extended lymph node
dissections. Despite the increased number of lymph nodes resected, there was no survival
benefit but an increased morbidity.9–11
There are no studies addressing the significance of direct lymph node invasion by pancreatic
adenocarcinoma (Fig. 1). Our first aim was to determine the frequency and prognostic
impact of direct lymph node invasion. Our second aim was to determine the impact of the
lymph node ratio (LNR, ratio of positive nodes to total nodes) on overall survival.
Materials and Methods
Study Design
Review of a retrospectively created database (1/1/1993–1/1/2001) and a prospectively
maintained database (1/1/2001–7/31/2008) was performed to identify patients who
underwent surgical resection of pancreatic ductal adenocarcinoma. Patients with pancreatic
adenocarcinoma arising within intraductal papillary mucinous neoplasms were excluded.
Clinical data evaluated included gender, age, race, family history, presenting symptoms
(presence of abdominal pain and jaundice), operative procedures, neoadjuvant and adjuvant
therapy, and disease-specific survival. Pathological data evaluated included TNM stage, size
of the tumor, histological type, degree of differentiation, perineural, lymphatic, perivascular
invasion, and surgical margin status. Tumors were graded as poorly, moderately, or well
differentiated. Operative mortality was defined as death within 30 days of the operation.
Overall survival was measured from the date of surgery until the time of death or last
follow-up. Patients were staged according to the AJCC 6th edition.
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Patients with positive lymph nodes were divided into two groups, direct and regional. Direct
invasion of a node by tumor was defined by the presence of a continuous column of tumor
cells extending from the intra- or extrapancreatic portion of the primary lesion to the
involved lymph node. Regional nodal metastasis lacked this continuity between the primary
pancreatic lesion and the lymph node. For lymph nodes directly invaded by the tumor, the
available pathology slides were reviewed by a single GI pathologist (V.D.). For node-
positive patients, the ratio of the number of positive nodes to the total number of nodes
resected was calculated (LNR). The period from 1/1/1993 to 7/31/2008 was divided into
three time periods (A: 1993–1997, B: 1998–2002, and C: 2003–2008) in order to assess
changes in the number of assessed lymph nodes.
This study was approved by the Institutional Review Board of the Massachusetts General
Hospital.
Statistical Analysis
Statistical analysis of the data was done utilizing SPSS 11.0 for windows (Statistical
Package for the Social Sciences, Inc., Chicago, IL). Continuous variables including age,
tumor size, and LNR were dichotomized at their median values for the purpose of statistical
analysis. Comparisons for continuous variables with normal distributions were conducted
with the t test and for continuous variables without normal distributions by the Mann–
Whitney test or Kruskal–Wallis test. Categorical variables were analyzed using the chi-
square test. Survival curves were constructed with the Kaplan–Meier method. Univariate
comparisons were performed with the log-rank method. Cox proportional hazards model
was used for those factors found to be significant in the univariate analysis. Level of
statistical significance was set at p=0.05.
Results
Clinicopathologic Characteristics
A total of 517 patients underwent resection for a pancreatic ductal adenocarcinoma, of
whom 52.8% were females. The clinicopathologic characteristics of the patients and the
operations performed are listed in Table 1. The median age of the cohort was 67 years old.
Pancreaticoduodenectomy was the most frequent operation performed (84.3%). The
majority of patients (67.5%) had Stage IIB disease with a median tumor size of 3 cm (range
0.3–12.5 cm).
The postoperative mortality was 0.8%. Median and mean follow-up were 16 and 24.9
months, respectively (range 0–166 months). The median survival for the entire cohort
(n=517) was 19.7 months, and the 5-year actuarial survival was 17.3%. Patients with node-
positive disease (n=349) had a statistically significant decrease in median and 5-year
survival compared to patients with node-negative disease (n=168) (16.4 versus 30.8 months
and 5-year actuarial survival of 9% versus 31%, respectively; p<0.001).
Patterns of Lymph Node Involvement: Direct Invasion versus Regional
The clinicopathologic characteristics of patients with direct lymph node invasion and
positive regional lymph nodes were similar (Table 1). A single positive lymph node was
identified in 89 patients (17.2%). Direct node invasion was present in 26 patients (29.2%),
and a positive regional node was present in 63 patients (70.8%). Two positive lymph nodes
were identified in 79 patients (15.3%). Direct invasion of both nodes occurred in six patients
(7.6%), two positive regional nodes were identified in 68 patients (86%), and five patients
had both direct and regional nodes (6.3%). No patients with three or more positive lymph
nodes had all their nodes directly invaded by the tumor. Therefore, we limited our analysis
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to patients with one or two positive nodes. Patients who had both direct and regional lymph
node involvement were also excluded from further analysis. The location of the tumor (head
versus body/tail) did not differ significantly between patients with one or two directly
invaded nodes (p=0.43). Overall survival for patients with one or two directly invaded nodes
was not significantly different from patients with one or two positive regional nodes
(p=0.67; Fig. 2).
Number of Lymph Nodes and Survival
The median number of pathologically examined lymph nodes for all patients was 13 (range
1–49). The number of nodes evaluated increased over time (Table 2).
Node-negative patients had a median survival of 30.8 months, a 5-year survival of 31% and
a median number of 10 lymph nodes assessed. In node-negative patients, overall survival did
not differ between those who had ≥10 nodes evaluated (n=85) and patients with <10 nodes
evaluated (n= 83; p=0.69). However, patients who were node-negative with <10 nodes had a
survival approaching that of patients with one positive node (p=0.11).
Node-positive patients had a median survival of 16.4 months and a 5-year survival of 9%.
For patients with node-positive disease, the median number of assessed lymph nodes was
15. The overall median survival for these patients was 16.4 months whether or not they had
<15 nodes assessed (p=0.5, Fig. 3).
The median number of positive lymph nodes was 3. Patients with a single positive node had
a significantly better survival than patients with two or more positive nodes (22.3 months for
one positive node vs. 16 months for two positive nodes vs. 15 months for >2 positive nodes;
log rank, p<0.001, Fig. 4). The median lymph node ratio was 0.2. The survival of patients
with a LNR of ≥0.2 (n= 181) was significantly worse than patients with a LNR< 0.2 (n=168;
14 vs. 22 months, respectively, p<0.001; Fig. 5).
Multivariate Survival Analysis
For the entire cohort of 517 patients, the median survival was 19.7 months, and the 5-year
actuarial survival was 17.3%. On univariate analysis, predictors of survival were: size and
differentiation of the tumor, presence of lymphatic and perivascular invasion, negative
surgical margins (R0), and LNR.
Patients harboring well-differentiated tumors less than 3 cm in size, with no evidence of
perivascular or lymphatic invasion and a LNR less than 0.2 that were resected with
microscopically negative surgical margins had the most favorable outcome. After Cox
proportional hazards multivariate analysis, LNR remained the most significant prognostic
factor for survival (Table 3).
Discussion
Lymph node involvement by cancer is consistently a significant prognostic factor for overall
survival in patients with resected pancreatic adenocarcinoma.3–7 In this report, node-
negative patients experienced a 5-year actuarial survival of 31%, whereas node-positive
patients had a 5-year actuarial survival of 9%. While many studies outline the importance of
lymph node involvement, no prior studies address the impact of direct tumor extension into
lymph nodes.
Direct lymph node invasion was documented in 29.2% of patients with a single positive
node and in 7.6% of patients with two positive nodes. The probability of identifying direct
lymph node invasion by the tumor was similar for resected cancers located in the head,
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body, and tail of the pancreas. Patients with positive regional nodes can harbor earlier stage
tumors (T1/T2) than patients with extrapancreatic extension of the tumor into lymph nodes
(T3). However, there was no survival difference between patients with positive direct or
regional nodes.
Increased awareness of the prognostic significance of lymph node positivity has led to
improved lymph node retrieval. In our cohort, the median number of examined nodes
increased progressively from 1993 to 2008. A significantly larger number of nodes were
retrieved in node-positive patients, which has been described in other surgical series as
well.6,12
In our study, evaluating more lymph nodes than the median number of nodes was not
associated with improved survival in either the N0 or N1 groups. Node-negative patients had
a survival of 30.8 months, similar to the 25.3 months in the series by Pawlik et al.13 and 27
months in the series by House et al.6 The survival benefit of node-negative disease seems to
be lost when the patient is characterized as node-negative based on a small number of
assessed lymph nodes. House et al.6 reported that patients characterized as N0 based on less
than 12 nodes had a similar survival to patients with a single positive node and more than 12
nodes assessed. We similarly found that patients characterized as node-negative based on
less than 10 nodes assessed had a similar survival to patients with one positive node. The
effect of the total number of assessed lymph nodes on survival has been examined in
multiple studies using the SEER database.12,14,15 These studies suggest that patients should
have at least 15 nodes assessed to be adequately staged which emphasizes the need for both
careful surgical dissection and pathologic assessment.
The median survival of N1 patients was 16.4 months, similar to the 16 months reported by
House et al.6 and 16.5 by Pawlik et al.13 A single positive lymph node was identified in
25.6% of patients, similar to the 28% reported by House et al.6 Tomlinson et al.14 identified
a single positive node in 60% of the patients in the SEER database. However, the median
number of assessed lymph nodes in the SEER database was only 7, a factor which could
contribute to the high number of patients with a single positive node among the N1 group. In
our series, patients with one positive node had a better survival when compared to patients
with two positive nodes. However, the presence of more than two positive nodes was not
associated with a further decrease in survival.
Recent series have emphasized the importance of the ratio of positive to total lymph nodes
(LNR) as a prognostic tool in many GI cancers, including the esophagus,16 stomach,17,18
colon,19 and pancreatic adenocarcinoma.13,20,21 In our study, the median lymph node ratio
was 0.2, and patients with a LNR higher than 0.2 had a significantly worse prognosis. The
LNR remained highly significant on multivariate analysis. The cutoff values associated with
the greatest differences in survival were 0.15 and 0.16, similar to the 0.18 value reported by
House et al.6
Potential weaknesses of this study are related to its retrospective nature. Although the
pathologic description of the gross specimen at our institution includes the location of the
positive lymph nodes, it is possible that the rate of direct invasion is underreported.
Prospectively performed studies in pancreatic ductal adenocarcinoma are needed to address
the true rate and prognostic significance of direct lymph node invasion.
Conclusion
Isolated direct lymph node invasion by pancreatic ductal adenocarcinoma occurs in at least
20% of patients with one or two positive lymph nodes. The number of positive lymph nodes,
not the mechanism of lymph node involvement, is a significant predictor of overall survival.
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Patients with a single positive lymph node have an improved survival compared to patients
with two or more positive nodes. The LNR remains a powerful prognostic tool after
adjusting for other prognostic factors.
Acknowledgments
We would like to thank Hyacinth Haggarty and Ana Miranda from the Health Information Services and Carol
Venuti from the Tumor Registry of the Massachusetts General Hospital for their precious help.
This research is being supported by the Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research, Boston
and by the Lantzounis research grant of the Hellenic Medical Society of New York.
References
1. American Cancer Society. www.cancer.org
2. Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J
Gastrointest Surg. 2008; 12 (4):701–706. [PubMed: 18027062]
3. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic
cancer: a single-institution experience. J Gastrointest Surg. 2006; 10(9):1199–210. discussion 1210–
1. [PubMed: 17114007]
4. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for
pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008; 247(3):456–462. [PubMed:
18376190]
5. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma:
analysis of actual 5-year survivors. J Am Coll Surg. 2004; 198(5):722–731. [PubMed: 15110805]
6. House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in
patients with resected pancreatic cancer. J Gastrointest Surg. 2007; 11(11):1549–1555. [PubMed:
17786531]
7. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic
adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;
237(1):74–85. [PubMed: 12496533]
8. Ishikawa O, Ohigashi H, Sasaki Y, et al. Practical grouping of positive lymph nodes in pancreatic
head cancer treated by an extended pancreatectomy. Surgery. 1997; 121(3):244–249. [PubMed:
9068665]
9. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated
with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the
pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study. Group Ann
Surg. 1998; 228 (4):508–517.
10. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal
gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma,
part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;
236(3):355–366. discussion 366–8. [PubMed: 12192322]
11. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard
pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in
resectable pancreatic head adenocarcinoma. Surgery. 2005; 138(4):618–628. discussion 628–30.
[PubMed: 16269290]
12. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival:
information from a large US population database. Ann Surg Oncol. 2006; 13(9):1189–1200.
[PubMed: 16955385]
13. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following
pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007; 141(5):610–618. [PubMed:
17462460]
14. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a
potential quality measure. Arch Surg. 2007; 142(8):767–723. discussion 773–4. [PubMed:
17709731]
Konstantinidis et al. Page 6













15. Hellan M, Sun CL, Artinyan A, et al. The impact of lymph node number on survival in patients
with lymph node-negative pancreatic cancer. Pancreas. 2008; 37(1):19–24. [PubMed: 18580439]
16. Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and
ratio in esophageal cancer. J Surg Res. 2008; 146(1):11–15. [PubMed: 18028955]
17. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric
carcinoma. Ann Surg Oncol. 2002; 9 (1):27–34. [PubMed: 11829427]
18. Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an
independent prognostic factor after D2 resection for gastric cancer: analysis of a large European
monoinstitutional experience. Ann Surg Oncol. 2003; 10(9):1077–1085. [PubMed: 14597447]
19. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing
number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol.
2003; 21(15):2912–2919. [PubMed: 12885809]
20. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an
important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am
Surg. 2004; 70(3):235–240. discussion 240. [PubMed: 15055847]
21. Smith RA, Bosonnet L, Ghaneh P, et al. Preoperative CA19–9 levels and lymph node ratio are
independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig
Surg. 2008; 25(3):226–232. [PubMed: 18577869]
Konstantinidis et al. Page 7














In direct invasion (arrowheads) the tumor is directly invading lymph nodes situated in the
peripancreatic fat (P pancreas, PF peripancreatic fat, LN lymph node).
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Patients with one or two positive nodes have similar survival whether the node is directly
invaded by the tumor (A), or is a regional node (B).
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Median number of nodes evaluated in patients with positive nodes does not affect survival.
A Total number of resected nodes ≥15; B N1 patients with resected nodes <15.
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Patients with negative nodes have a better prognosis compared to patients with one, two, or
more than two positive nodes.
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The influence of LNR on overall survival; A LNR≥0.2; B LNR<0.2.
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Table 1
Clinicopathologic Characteristics of 517 Patients with Resected Pancreatic Adenocarcinoma
All Patients Direct Regional P value
Number of patients (%) 517 32 131
Age median (range) 67 (33–90) 69.5 (47–82) 68 (43–90) 0.85
Female gender 273 (52.8) 21 (65.6) 66 (50.3) 0.12
Abdominal pain 225 (43.5) 13 (40.6) 54 (41.2) 0.94
Jaundice 345 (66.7) 21 (65.6) 83 (63.3) 0.64
Operations
 Pancreaticoduodenectomy 436 (84.3) 25 (78.1) 109 (83.2) 0.5
 Distal pancreatectomy 73 (14.1) 7 (21.9) 22 (16.8)
 Total pancreatectomy 8 (1.5) 0 0
Surgical margins R0 360 (69.6) 24 (75) 97 (74) 0.91
Median tumor size, cm (range) 3 (0.3–12.5) 2.6 (1–7) 3 (0–7) 0.43
T stage
 T1 19 (3.7) 0 1 (0.8) 0.23
 T2 40 (7.7) 0 10 (7.6)
 T3 458 (88.6) 32 (100) 120 (91.6)
Grade
 Well 18 (3.5) 1 (3.1) 6 (4.6) 0.75
 Mod 282 (54.5) 19 (59.4) 67 (51.1)
 Poor 205 (39.7) 12 (37.5) 55 (42)
 Other (not assessed, undifferentiated, mixed types) 12 (2.3) 0 3 (2.3)
Perineural invasion 407 (78.7) 30 (93.7) 104 (79.4) 0.05
Lymphatic invasion 220 (42.6) 17 (53.1) 55 (42) 0.25
Vascular invasion 222 (42.9) 13 (40.6) 52 (39.7) 0.92
Patients with one or two positive nodes are divided into direct and regional (p values reflect the comparison between direct and regional LN groups
with one or two positive nodes)













Konstantinidis et al. Page 14
Table 2
Factors Influencing the Number of Assessed Lymph Nodes
(Parameter) Median Number of LNs P value
Time period
 1993–1997 (105) 9 <0.001
 1998–2002 (161) 13
 2003–2008 (251) 15
Operation
 Whipple (436) 14 0.1
 Distal pancreatectomy (73) 12
 Total pancreatectomy (8) 19
Tumor stage
 Intrapancreatic (T1,T2) (59) 13 0.26
 Extrapancreatic (T3) (458) 14
Nodal status
 N0 (168) 10 <0.001
 N1 (349) 15
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Table 3
Univariate and Multivariate Analysis of Prognostic Factors
Factor Univariate P value Multivariate P value
Size≥3 cm <0.0001 0.003
Differentiation 0.044 0.003
LNR≥0.2 <0.0001 <0.0001
Perivascular Invasion 0.0002 0.06
Lymphatic Invasion 0.0047 0.19
R0 <0.0001 0.005
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